BACKGROUND: Patient blood management (PBM) is a multidisciplinary concept focused on the management of anaemia, minimisation of iatrogenic blood loss and rational use of allogeneic blood products. The aims of this study were: (i) to analyse post-operative outcome in patients with liberal vs restrictive exposure to allogeneic blood products and (ii) to evaluate the cost-effectiveness of PBM in patients undergoing surgery. MATERIALS AND METHODS: A systematic literature review and meta-analysis were performed to compare post-operative complications in predominantly non-transfused patients (restrictive transfusion group) and patients who received one to three units of red blood cells (liberal transfusion group). Outcome measures included sepsis with/without pneumonia, acute renal failure, acute myocardial infarction and acute stroke. In a second step, a health economic model was developed to calculate cost-effectiveness of PBM (PBM-arm vs control-arm) for simulated cohorts of 10,000 cardiac and non-cardiac surgical patients based on the results of the meta-analysis and costs. RESULTS: Out of 478 search results, 22 studies were analysed in the meta-analysis. The pooled relative risk of any complication in the restrictive transfusion group was 0.43 for non-cardiac and 0.34 for cardiac surgical patients. In the simulation model, PBM was related to reduced complications (1,768 vs 1,245) and complication-related deaths (411 vs 304) compared to standard care. PBM-related costs of therapy exceeded costs of the control arm by € 150 per patient. However, total costs, including hospitalisation, were higher in the control-arm for both non-cardiac (€ 2,885.11) and cardiac surgery patients (€ 1,760.69). The incremental cost-effectiveness ratio including hospitalisation showed savings of € 30,458 (non-cardiac and cardiac surgery patients) for preventing one complication and € 128,023 (non-cardiac and cardiac surgery patients) for prevention of one complication-related death in the PBM-arm. DISCUSSION: Our results indicate that PBM may be associated with fewer adverse clinical outcomes compared to control management and may, thereby, be cost-effective.
BACKGROUND:Patient blood management (PBM) is a multidisciplinary concept focused on the management of anaemia, minimisation of iatrogenic blood loss and rational use of allogeneic blood products. The aims of this study were: (i) to analyse post-operative outcome in patients with liberal vs restrictive exposure to allogeneic blood products and (ii) to evaluate the cost-effectiveness of PBM in patients undergoing surgery. MATERIALS AND METHODS: A systematic literature review and meta-analysis were performed to compare post-operative complications in predominantly non-transfused patients (restrictive transfusion group) and patients who received one to three units of red blood cells (liberal transfusion group). Outcome measures included sepsis with/without pneumonia, acute renal failure, acute myocardial infarction and acute stroke. In a second step, a health economic model was developed to calculate cost-effectiveness of PBM (PBM-arm vs control-arm) for simulated cohorts of 10,000 cardiac and non-cardiac surgical patients based on the results of the meta-analysis and costs. RESULTS: Out of 478 search results, 22 studies were analysed in the meta-analysis. The pooled relative risk of any complication in the restrictive transfusion group was 0.43 for non-cardiac and 0.34 for cardiac surgical patients. In the simulation model, PBM was related to reduced complications (1,768 vs 1,245) and complication-related deaths (411 vs 304) compared to standard care. PBM-related costs of therapy exceeded costs of the control arm by € 150 per patient. However, total costs, including hospitalisation, were higher in the control-arm for both non-cardiac (€ 2,885.11) and cardiac surgery patients (€ 1,760.69). The incremental cost-effectiveness ratio including hospitalisation showed savings of € 30,458 (non-cardiac and cardiac surgery patients) for preventing one complication and € 128,023 (non-cardiac and cardiac surgery patients) for prevention of one complication-related death in the PBM-arm. DISCUSSION: Our results indicate that PBM may be associated with fewer adverse clinical outcomes compared to control management and may, thereby, be cost-effective.
Authors: Victor A Ferraris; Daniel L Davenport; Sibu P Saha; Alethea Bernard; Peter C Austin; Joseph B Zwischenberger Journal: Ann Thorac Surg Date: 2011-04-23 Impact factor: 4.330
Authors: A G Kleinerüschkamp; K Zacharowski; C Ettwein; M M Müller; C Geisen; C F Weber; P Meybohm Journal: Anaesthesist Date: 2016-05-09 Impact factor: 1.041
Authors: Ludhmila A Hajjar; Jean-Louis Vincent; Filomena R B G Galas; Rosana E Nakamura; Carolina M P Silva; Marilia H Santos; Julia Fukushima; Roberto Kalil Filho; Denise B Sierra; Neuza H Lopes; Thais Mauad; Aretusa C Roquim; Marcia R Sundin; Wanderson C Leão; Juliano P Almeida; Pablo M Pomerantzeff; Luis O Dallan; Fabio B Jatene; Noedir A G Stolf; Jose O C Auler Journal: JAMA Date: 2010-10-13 Impact factor: 56.272
Authors: Niels Straub; Ekaterina Bauer; Seema Agarwal; Patrick Meybohm; Kai Zacharowski; Alexander A Hanke; Christian F Weber Journal: Clin Lab Date: 2016 Impact factor: 1.138
Authors: Chen Rubinstein; Daniel L Davenport; Rebekah Dunnagan; Sibu P Saha; Victor A Ferraris; Eleftherios S Xenos Journal: J Vasc Surg Date: 2013-02 Impact factor: 4.268
Authors: T Schwermann; M Grotz; M Blanke; S Ruchholtz; R Lefering; J M Graf V d Schulenburg; C Krettek; H C Pape Journal: Unfallchirurg Date: 2004-07 Impact factor: 1.000
Authors: Ani C Anyanwu; Farzan Filsoufi; Sacha P Salzberg; David J Bronster; David H Adams Journal: J Thorac Cardiovasc Surg Date: 2007-11 Impact factor: 5.209
Authors: Eric A J Hoste; Gilles Clermont; Alexander Kersten; Ramesh Venkataraman; Derek C Angus; Dirk De Bacquer; John A Kellum Journal: Crit Care Date: 2006-05-12 Impact factor: 9.097
Authors: Thomas Drabinski; Kai Zacharowski; Patrick Meybohm; Alexandra M Rüger; Antonio Ramirez de Arellano Journal: Adv Ther Date: 2020-06-19 Impact factor: 3.845